ArticleCancer medicine2021

Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study.

Rui Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.